

Utility Patent
Ser. No. 10/564,861

CLAIM AMENDMENTS

Please amend Claim 1 (~~strikethrough~~ for deletion and underline for insertion):

1. (Currently amended) A method ~~for~~ of treatment for lung carcinoma, breast cancer, gastric cancer, and colon cancer, kidney cancer, pancreatic cancer, malignant melanoma, and malignant and low differentiated lymphoma, and certain oncological diseases, said method comprises a step of introducing a treatment agent into a circulating blood system of a cancer patient diagnosed with at least one of the foregoing cancers and diseases, said treatment agent destroys extracellular DNA in said blood of said cancer patient, wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme; and wherein said treatment agent is administered in doses and regimens which provide blood plasma DNA-hydrolytic activity, - measured in blood plasma, to exceed 150 Kunitz units per liter of plasma during more than then 12 hours in total within 24 hours.
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) The method according to claim 1 ~~3~~, wherein doses of said treatment are introduced to the patient according to a regime schedule which is carried out continuously ~~for~~ during no less than 48 hours-uninterruptedly.

Utility Patent
Ser. No. 10/564,861

5. (Cancelled).
6. (Currently Amended) The method according to claim 1, wherein bovine pancreatic DNase is said agent used to destroy said extracellular DNA, said bovine pancreatic DNase is parenterally introduced in doses ranging from 50,000 Kunitz units to 250,000,000 Kunitz units a day for 5-360 days.
7. (Previously Presented) The method according to claim 1, wherein human recombinant DNase I is used.
8. (Currently Amended) The method according to claim 7, wherein human recombinant DNase I (Dornase alpha) is parenterally introduced in doses 1,15 mg/kg-500mg/kg of body weight daily during 5-360 days.
9. (Currently Amended) The method according to claim 1, wherein the treatment is carried out from a diagnosis of the cancer and to for a remaining term of the patient's life.
10. (Previously Presented) The method according to claim 1, further including a step of introducing a binding agent into said blood system, said binding agent binds said extracellular DNA.

Utility Patent
Ser. No. 10/564,861

11. (Previously Presented) The method according to claim 10, wherein said binding agent is anti-DNA antibodies.
12. (Previously Presented) The method according to claim 1, further comprising a step of introducing a modifying agent into said blood system, wherein said modifying agent modifies one or all of a chemical composition, a conformation, a degree of polymerization, or an association with proteins, lipids and/or ribonucleic acids of said extracellular DNA.
13. (Previously Presented) The method according to claim 12, wherein said modifying agent is a ribonuclease enzyme.
14. (Cancelled)
15. (Newly Added) A method of treatment for lung carcinoma, breast cancer, gastric cancer, and colon cancer, kidney cancer, pancreatic cancer, malignant melanoma, and malignant and low differentiated lymphoma, and certain oncological diseases, said method comprises a step of introducing a treatment agent into a circulating blood system of a cancer patient diagnosed with at least one of the foregoing cancers and diseases, said treatment agent destroys extracellular DNA in said blood of said cancer patient,
- wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme; and,
- wherein said agent is introduced in doses sufficient to provide an electrophoretic profile

**Utility Patent
Ser. No. 10/564,861**

change in the extracellular DNA of said patient; and,

wherein said change is revealed by means of pulse-gel electrophoresis.